In yesterday’s Wall Street session, Emergent Biosolutions Inc (NYSE:EBS) shares traded at $11.43, down -4.91% from the previous session.
EBS stock price is now 74.37% away from the 50-day moving average and 240.07% away from the 200-day moving average. The market capitalization of the company currently stands at $598.93M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $5, The Benchmark Company recently Upgraded its rating from Hold to Buy for Emergent Biosolutions Inc (NYSE: EBS). , while ‘The Benchmark Company’ rates the stock as ‘Hold’
In other news, Zoon Kathryn C, Director sold 10,000 shares of the company’s stock on Jun 04 ’24. The stock was sold for $61,100 at an average price of $6.11. Upon completion of the transaction, the Director now directly owns 54,482 shares in the company, valued at $0.62 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 29 ’24, Director Zoon Kathryn C sold 1,830 shares of the business’s stock. A total of $8,436 was realized by selling the stock at an average price of $4.61. This leaves the insider owning 64,482 shares of the company worth $0.74 million. A total of 4.23% of the company’s stock is owned by insiders.
During the past 12 months, Emergent Biosolutions Inc has had a low of $1.42 and a high of $12.74. As of last week, the company has a debt-to-equity ratio of 1.39, a current ratio of 1.08, and a quick ratio of 0.55. The fifty day moving average price for EBS is $6.8076 and a two-hundred day moving average price translates $3.4251 for the stock.
The latest earnings results from Emergent Biosolutions Inc (NYSE: EBS) was released for 2024-03-31. The net profit margin was -47.68% and return on equity was -60.56% for EBS. The company reported revenue of $300.4 million for the quarter, compared to $164.3 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 82.84 percent.
